AL-S Pharma Presents Phase 2 AP-101 Data at ENCALS 2026, Highlighting Potential Disease-Modifying Effects in ALS
AL-S Pharma AG, a clinical-stage biotechnology company focused on developing antibody therapies against misfolded proteins associated with amyotrophic lateral sclerosis (ALS), has presented new clinical data from its global Phase 2 AP-101-02 trial evaluating AP-101, the company’s lead investigational therapy for ALS. The findings were shared in a poster presentation at the European Network to Cure ALS (ENCALS) 2026 Congress, offering fresh evidence that the therapy may have the potential to modify disease progression in people living with this devastating neurodegenerative disorder.
The company said the Phase 2 results build on the previously reported safety and tolerability profile of AP-101 and provide additional support for the role of misfolded superoxide dismutase 1 (SOD1) as a relevant therapeutic target in ALS. According to AL-S Pharma, the latest analyses suggest that treatment with AP-101 may be associated with prolonged survival, delayed need for ventilatory support, reductions in neuroaxonal injury biomarkers, and signals of disease stabilization across both sporadic ALS patients and individuals carrying SOD1 mutations.
The data are important for AL-S Pharma as it prepares to move AP-101 into a confirmatory Phase 3 clinical trial, which the company expects to initiate in the first quarter of 2027. If successful, AP-101 could emerge as a potential disease-modifying therapy in a field where treatment options remain limited and the need for new approaches is acute.
Targeting Misfolded SOD1 in a Complex Disease
ALS is a progressive neurodegenerative disease that affects nerve cells responsible for controlling voluntary muscle movement, ultimately leading to muscle weakness, loss of mobility, difficulty speaking and swallowing, respiratory failure, and death. Although the disease is often discussed in terms of familial and sporadic forms, ALS is increasingly understood as biologically heterogeneous, with multiple genetic, molecular, and cellular mechanisms contributing to disease onset and progression.
One of the best-studied proteins in ALS biology is superoxide dismutase 1 (SOD1). Mutations in the SOD1 gene are known to cause a subset of inherited ALS cases, but growing research suggests that misfolded, toxic forms of SOD1 may also play a role more broadly in ALS pathology, potentially extending beyond patients with known SOD1 mutations. This concept has helped drive interest in therapies designed to interfere with the accumulation and spread of abnormal SOD1 species in the nervous system.
AP-101 is designed around that premise. AL-S Pharma describes the therapy as an investigational human-derived antibody that selectively targets the misfolded toxic form of SOD1 while sparing the normal version of the protein. The goal is to interrupt the progressive spread of misfolded SOD1 through the nervous system, thereby slowing disease propagation and supporting the body’s ability to clear the harmful protein.
By focusing on a misfolded protein believed to contribute to neuronal injury and disease progression, AP-101 is being positioned as a therapy with the potential not just to address symptoms, but to alter the underlying course of ALS.
Phase 2 Trial Met Safety Endpoint and Produced Additional Biomarker and Survival Signals
According to AL-S Pharma, the global AP-101-02 Phase 2 clinical trial met its primary endpoint of safety and tolerability, an important milestone in the development of any biologic therapy intended for chronic use in a vulnerable patient population. The company reported that adverse events in the AP-101 treatment arm were similar to those observed in the placebo group, and notably, no antibody responses induced by AP-101 were reported, an encouraging sign from an immunogenicity standpoint.
Beyond safety, the company said recent analyses from the study offer additional evidence of what it describes as clinically meaningful disease modification. Among the key findings were reductions in serum neurofilament light chain (NfL) and cerebrospinal fluid phosphorylated neurofilament heavy chain (pNfH) after six months of treatment. Both NfL and pNfH are widely studied biomarkers of neuroaxonal injury and neuronal damage in ALS and other neurodegenerative diseases. Lower levels of these markers may indicate a reduction in ongoing neuronal injury, making them important readouts in efforts to evaluate whether an investigational therapy is affecting disease biology.
The company believes these biomarker changes strengthen the case that AP-101 may be influencing underlying disease mechanisms rather than simply providing symptomatic benefit. In ALS, where progression can be relentless and therapeutic effects are often difficult to capture, biomarker shifts that align with clinical outcomes are viewed as particularly valuable.
Exploratory Analysis Suggests Benefit on Survival and Ventilatory Support
One of the most notable aspects of the presentation involved a prespecified analysis of an exploratory composite endpoint. According to AL-S Pharma, this analysis indicated that early treatment with AP-101 prolonged survival and delayed the need for ventilatory support compared with participants who initially received placebo for six months and then crossed over to AP-101 for the following six months.
The company reported that positive treatment effects were seen in both the sporadic ALS cohort and the SOD1 mutation carrier cohort, with statistical significance observed in each group. In the sporadic ALS population, the reported p-value was 0.013, while in the SOD1 mutation carrier group it was 0.036. Although exploratory analyses must be interpreted carefully, the findings are notable because they suggest that the therapeutic relevance of misfolded SOD1 may extend beyond the genetically defined SOD1-ALS population.
AL-S Pharma also said that survival-related benefits were accompanied by disease stabilization as measured by King’s staging, a clinical staging system used to track disease progression in ALS. In addition, functional decline measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) was reportedly reduced in study participants who had elevated levels of misfolded SOD1 at baseline and in those carrying SOD1 mutations.
Taken together, these findings point to a treatment effect that may be biologically and clinically meaningful, particularly if the benefits can be reproduced in a larger, confirmatory study. For a disease like ALS—where even modest slowing of progression can be deeply meaningful to patients and families—signals involving survival, respiratory support, and functional decline carry substantial weight.
Company Sees Data as Support for AP-101 as a Potential Disease-Modifying Therapy
Angela Genge, M.D., FRCP(C), eMBA, Chief Medical Officer of AL-S Pharma, said the results reinforce the importance of misfolded SOD1 as a therapeutic target in ALS, even in the context of a disease that is highly diverse and biologically complex. She noted that the consistency seen across multiple biomarker and clinical measures provides a strong rationale for continued development of AP-101 and supports its potential as a disease-modifying therapy.
Genge said the company remains focused on advancing the AP-101 clinical program and ultimately bringing a much-needed new treatment option to people living with ALS. Her comments reflect the broader strategic challenge facing ALS drug developers: translating increasingly sophisticated insights into disease biology into therapies that can demonstrate real-world clinical benefit in a heterogeneous patient population.
For AL-S Pharma, the Phase 2 data appear to serve two purposes at once. First, they provide support for the scientific hypothesis that misfolded SOD1 may be a therapeutically relevant driver of ALS progression. Second, they help build the clinical package needed to justify advancement into Phase 3, where the therapy will face the more rigorous test of confirmatory efficacy evaluation.
Phase 3 Program Planned for 2027
With Phase 2 results now in hand, AL-S Pharma said it is moving AP-101 into a confirmatory Phase 3 clinical trial in ALS, with study initiation targeted for the first quarter of 2027. That next stage will be critical in determining whether the encouraging safety, biomarker, and exploratory efficacy findings seen in Phase 2 can translate into a robust demonstration of benefit in a larger patient population.
AP-101 has already received Orphan Drug designation from the U.S. Food and Drug Administration, the European Medicines Agency, and Swissmedic, designations that reflect the seriousness of ALS, the lack of sufficient treatment options, and the importance of encouraging the development of therapies for rare diseases. Orphan designation can provide a range of incentives, including regulatory support and potential market exclusivity if the therapy is ultimately approved.
For a company at AL-S Pharma’s stage, these designations are strategically important because they can help de-risk development and improve the commercial attractiveness of a successful product in a rare but high-need disease area.
ENCALS Symposium Explores the Evolving Biology of ALS
In addition to the poster presentation, AL-S Pharma also hosted a symposium at ENCALS 2026 titled “Beyond ‘Sporadic’ ALS: Genetics, Biomarkers, and the Misfolded SOD1 Pathway.” Moderated by Dr. Genge, the session brought together several prominent leaders in ALS research to examine how new insights into genetics, biomarker science, and protein misfolding biology are reshaping both therapeutic development and clinical trial design.
The symposium was aimed at neurologists, physician-scientists, clinical investigators, and industry professionals involved in ALS drug development. Its focus was on bridging emerging scientific understanding with the practical realities of diagnosing ALS, stratifying patients for trials, interpreting biomarkers, and designing more effective studies.
Among the speakers was Prof. Ammar Al-Chalabi, who revisited the long-standing distinction between familial and sporadic ALS and argued for a more nuanced view of genetic contribution and disease architecture. As ALS genetics has evolved, the traditional binary classification of the disease has become less clear-cut, with increasing evidence that even apparently sporadic cases may carry meaningful genetic influences.
Prof. Dame Pamela Shaw addressed the role of neurofilament biomarkers in ALS clinical trials, discussing what they have revealed over time, how they are being used today, and how they should be interpreted in the context of therapeutic studies. Neurofilaments have become one of the most closely watched biomarker classes in ALS because they offer a potential window into ongoing neurodegeneration and treatment effect.
Prof. Philip Van Damme reviewed lessons from SOD1-ALS and explored the possibility that misfolded SOD1 could contribute to disease even in the absence of SOD1 mutations. This idea is central to the broader relevance of AP-101, since a therapy limited only to a very small genetically defined subgroup would have a narrower impact than one capable of addressing a wider ALS population.
The symposium concluded with a moderated panel discussion titled “Translating ALS Biology into Better Trials,” featuring Prof. Leonard van den Berg, Prof. Andrea Malaspina, and Prof. Julian Grosskreutz. The panel examined how insights from genetics, biomarker interpretation, and misfolded protein biology could be translated into improved trial design, more precise patient stratification, and better therapeutic development strategies.
A Broader Push Toward Biologically Driven ALS Treatment
The combination of Phase 2 data and scientific discussion at ENCALS reflects a larger movement within ALS research toward biologically driven treatment development. For decades, ALS drug development has been hindered by the disease’s complexity, rapid progression, and limited understanding of which molecular pathways are most important in which patients. Increasingly, however, researchers are seeking to define ALS not as a single disease but as a spectrum of related biological subtypes that may require more targeted intervention.
AL-S Pharma is attempting to position AP-101 within that emerging framework. By targeting misfolded SOD1 and linking treatment effects to biomarkers and patient subgroups, the company is making the case that its antibody could become part of a new generation of therapies designed around the biological mechanisms driving neurodegeneration.
Whether AP-101 can ultimately fulfill that promise will depend on the results of Phase 3. But with supportive safety data, encouraging biomarker changes, exploratory evidence of survival benefit, and growing scientific interest in the role of misfolded SOD1 beyond classic genetic ALS, the program is entering its next stage with momentum—and with the hopes of contributing a new therapeutic option to a field where every advance matters.
About AP-101-02
The AP-101-02 clinical trial (NCT05039099) was a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety, tolerability, pharmacodynamic markers, and pharmacokinetics (PK) of AP-101 in 73 patients with sporadic ALS and in patients with mutations in the superoxide dismutase 1 (SOD1) gene. Study participants with sporadic (n=52) or mutant SOD1 ALS (n=21) were stratified and randomized 2:1 to intravenous AP-101 or placebo every three weeks.
Key assessments included survival and ventilation endpoints, slow vital capacity, neurofilament levels, misfolded SOD1, PK, and anti-drug antibodies. After 24 weeks all participants entered a 24-week open-label extension with continued AP-101 treatment, followed by a 16-week safety follow-up period.
AP-101-02 was conducted in the U.S., Canada, the U.K., European Union, and South Korea. More information about the clinical trial can be accessed on www.clinicaltrials.gov.
About Amyotrophic Lateral Sclerosis and SOD1
Amyotrophic lateral sclerosis (ALS) is a relentless and progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord. Symptoms vary from person to person. Some forms of ALS begin with limb weakness, while others start with bulbar symptoms. All forms ultimately lead to loss of independence and a markedly shortened lifespan. Median survival remains three-to-five years, and diagnosis is often delayed.
Despite this diversity, many patients share common downstream pathologies involving axonal injury, inflammation, and protein misfolding. Superoxide dismutase 1 (SOD1) is a protective enzyme that helps cells manage oxidative stress. In ALS, structural changes can cause SOD1 to lose its proper function and misfold, taking on toxic conformations that disrupt cellular function. Such misfolded SOD1 can injure motor neurons, damage mitochondria, and impair axonal transport. Pathology can spread by the seeding of SOD1 misfolding.
Misfolded SOD1 represents a powerful therapeutic opportunity. Across different presentations of ALS, misfolded SOD1 can amplify axonal injury and accelerate disease progression, making these toxic conformations an important target for intervention.
About AL-S Pharma AG
AL-S Pharma is a clinical-stage biotech company developing AP-101 for the treatment of amyotrophic lateral sclerosis (ALS). Founded and co-owned by Neurimmune and TVM Capital Life Science, AL-S Pharma brings together a seasoned team of biotech and pharmaceutical leaders with expertise spanning drug discovery, translational research, and clinical development. AL-S Pharma is based in Zurich, Switzerland.
